Skip to main content

Telix Pharmaceuticals Ltd (TLX)

Red

Health Care · As of 17 July 2026

Price chart — 52 weeks

TLX · 10.46 (last weekly close) SMA 10w SMA 40w
46810121416AugSepOctNovDec2026FebMarAprMayJunJul2.0MWeek of Jul 21, 2025 · O 16.35 · H 16.94 · L 13.87 · C 14.20 · Vol 558KWeek of Jul 28, 2025 · O 13.95 · H 14.17 · L 12.90 · C 13.05 · Vol 283KWeek of Aug 4, 2025 · O 13.21 · H 14.27 · L 11.34 · C 11.34 · Vol 477KWeek of Aug 11, 2025 · O 11.20 · H 11.55 · L 10.70 · C 11.54 · Vol 500KWeek of Aug 18, 2025 · O 11.69 · H 12.60 · L 10.50 · C 12.48 · Vol 964KWeek of Aug 25, 2025 · O 12.50 · H 12.58 · L 9.48 · C 9.55 · Vol 2.4MWeek of Sep 1, 2025 · O 9.36 · H 9.44 · L 8.93 · C 9.06 · Vol 709KWeek of Sep 8, 2025 · O 9.01 · H 9.74 · L 8.94 · C 9.21 · Vol 1.2MWeek of Sep 15, 2025 · O 9.33 · H 10.00 · L 9.15 · C 9.98 · Vol 1.1MWeek of Sep 22, 2025 · O 9.87 · H 11.08 · L 9.69 · C 9.98 · Vol 1.5MWeek of Sep 29, 2025 · O 9.87 · H 10.33 · L 9.54 · C 10.28 · Vol 614KWeek of Oct 6, 2025 · O 10.06 · H 10.29 · L 9.57 · C 9.57 · Vol 464KWeek of Oct 13, 2025 · O 9.60 · H 11.29 · L 9.47 · C 10.80 · Vol 835KWeek of Oct 20, 2025 · O 10.72 · H 11.00 · L 10.50 · C 10.82 · Vol 456KWeek of Oct 27, 2025 · O 10.93 · H 11.00 · L 10.54 · C 10.66 · Vol 376KWeek of Nov 3, 2025 · O 10.61 · H 10.61 · L 9.60 · C 9.71 · Vol 421KWeek of Nov 10, 2025 · O 9.99 · H 10.25 · L 9.15 · C 9.34 · Vol 432KWeek of Nov 17, 2025 · O 9.25 · H 9.40 · L 8.76 · C 8.91 · Vol 512KWeek of Nov 24, 2025 · O 8.92 · H 9.98 · L 8.92 · C 9.95 · Vol 232KWeek of Dec 1, 2025 · O 9.86 · H 9.93 · L 9.37 · C 9.85 · Vol 600KWeek of Dec 8, 2025 · O 9.75 · H 10.03 · L 8.98 · C 9.03 · Vol 833KWeek of Dec 15, 2025 · O 8.91 · H 8.91 · L 7.72 · C 7.80 · Vol 1.2MWeek of Dec 22, 2025 · O 8.02 · H 8.15 · L 7.83 · C 8.03 · Vol 718KWeek of Dec 29, 2025 · O 7.92 · H 7.95 · L 7.49 · C 7.62 · Vol 1.0MWeek of Jan 5, 2026 · O 7.55 · H 7.71 · L 7.38 · C 7.56 · Vol 649KWeek of Jan 12, 2026 · O 7.56 · H 7.79 · L 7.31 · C 7.76 · Vol 1.0MWeek of Jan 19, 2026 · O 7.86 · H 7.86 · L 7.16 · C 7.61 · Vol 705KWeek of Jan 26, 2026 · O 7.60 · H 8.45 · L 7.25 · C 7.28 · Vol 852KWeek of Feb 2, 2026 · O 7.24 · H 7.44 · L 6.87 · C 7.10 · Vol 761KWeek of Feb 9, 2026 · O 7.02 · H 7.43 · L 6.34 · C 6.54 · Vol 1.1MWeek of Feb 16, 2026 · O 6.34 · H 7.90 · L 6.28 · C 7.69 · Vol 1.4MWeek of Feb 23, 2026 · O 6.88 · H 7.52 · L 6.41 · C 7.25 · Vol 2.2MWeek of Mar 2, 2026 · O 7.04 · H 7.63 · L 6.69 · C 7.52 · Vol 2.2MWeek of Mar 9, 2026 · O 7.31 · H 8.09 · L 7.20 · C 7.85 · Vol 997KWeek of Mar 16, 2026 · O 7.83 · H 8.96 · L 7.76 · C 8.75 · Vol 1.5MWeek of Mar 23, 2026 · O 8.81 · H 9.31 · L 8.62 · C 9.20 · Vol 1.2MWeek of Mar 30, 2026 · O 9.09 · H 9.59 · L 8.92 · C 9.13 · Vol 761KWeek of Apr 6, 2026 · O 9.20 · H 10.71 · L 9.05 · C 10.54 · Vol 941KWeek of Apr 13, 2026 · O 11.03 · H 11.48 · L 10.41 · C 10.74 · Vol 1.8MWeek of Apr 20, 2026 · O 10.74 · H 10.77 · L 10.06 · C 10.56 · Vol 823KWeek of Apr 27, 2026 · O 10.45 · H 11.30 · L 10.32 · C 11.26 · Vol 656KWeek of May 4, 2026 · O 11.28 · H 11.30 · L 10.61 · C 10.68 · Vol 595KWeek of May 11, 2026 · O 10.89 · H 11.04 · L 10.24 · C 10.56 · Vol 559KWeek of May 18, 2026 · O 10.47 · H 10.47 · L 9.46 · C 9.47 · Vol 631KWeek of May 25, 2026 · O 9.53 · H 9.76 · L 9.38 · C 9.43 · Vol 429KWeek of Jun 1, 2026 · O 9.46 · H 9.70 · L 8.69 · C 9.30 · Vol 1.3MWeek of Jun 8, 2026 · O 9.38 · H 9.60 · L 9.21 · C 9.56 · Vol 1.0MWeek of Jun 15, 2026 · O 9.73 · H 10.16 · L 9.50 · C 10.09 · Vol 1.1MWeek of Jun 22, 2026 · O 10.47 · H 11.07 · L 10.00 · C 10.66 · Vol 857KWeek of Jun 29, 2026 · O 11.04 · H 12.18 · L 11.04 · C 11.87 · Vol 913KWeek of Jul 6, 2026 · O 11.97 · H 12.23 · L 11.08 · C 11.14 · Vol 939KWeek of Jul 13, 2026 · O 11.10 · H 11.29 · L 10.17 · C 10.46 · Vol 496K10.46
Weekly candles over the last 52 weeks, split-adjusted, with 10- and 40-week moving averages; trading volume along the bottom. As of Jul 13, 2026.

OakBag could not build a reliable fair-value estimate for Telix Pharmaceuticals Ltd (TLX) — none of its valuation methods cleared the model's safety checks (typically a company running an operating loss, where a discount can't be trusted). At a recent price of $10.46 the traffic light is set so it looks expensive or risky, benchmarked against other Health Care names. This is a model output for research, not a price target or a recommendation.

Fair value vs. price

Current price
$10.46
Estimated fair value
Margin of safety

How the fair value is built

How is this computed?

Why not green?

  • Only one valuation method applies to this business — too thin to flag as a buy on its own.

Knock-out safety checks passed

  • Bankruptcy risk (Altman Z″)
  • Negative equity
  • Excessive leverage
  • Illiquid
  • Penny / micro-cap
  • Stale fundamentals
Piotroski F-score
0 / 9
Beneish M-score
-2.48

Quality & factor profile

Value -0.07
Quality -0.41
Profitability +0.00
Momentum -1.05
Growth +0.00
Low volatility -0.42

See the full analysis

Create a free OakBag account to unlock every valuation method, price history, watchlists and email alerts for TLX and 1,850+ other stocks.

No credit card · just an email

Frequently asked questions

Is Telix Pharmaceuticals (TLX) undervalued?

OakBag could not build a reliable fair-value estimate for Telix Pharmaceuticals Ltd — none of its valuation methods cleared the model's safety checks, which usually happens for a company running an operating loss. At a recent price of $10.46 the model looks expensive or risky. This is a model output, not investment advice.

What is margin of safety?

Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. It cannot be shown here because no reliable fair-value estimate could be built for this stock.

Does a green verdict mean I should buy TLX?

No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.

Other Health Care stocks

An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.